NOD2 polymorphisms in clinical phenotypes of common variable immunodeficiency disorders

Clinical and Experimental Immunology

Volumn 161, Issue 3, 2010, Pages 536-541

  Packwood, K ^a   Drewe, E ^c   Staples, E ^c   Webster, D ^d   Witte, T ^g   Litzman, J ^h   Egner, W ^e   Sargur, R ^e   Sewell, W ^f   Lopez Granados, E ^a,b   Seneviratne, S L ^a   Powell, R J ^c   Ferry, B L ^a   Chapel, H M ^a,f  

^a OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c QUEEN S MEDICAL CENTRE   (United Kingdom)

^d ROYAL FREE HOSPITAL   (United Kingdom)

^e NORTHERN GENERAL HOSPITAL   (United Kingdom)

^f Path links ^*  (United Kingdom)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

Antibody deficiency; Common variable immunodeficiency; Disease susceptibility resistance polymorphisms; Immunodeficiency primary; Immunogenetics

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; DNA;

ARTICLE; AUTOIMMUNE DISEASE; BRONCHIECTASIS; COMMON VARIABLE IMMUNODEFICIENCY; CROHN DISEASE; DISEASE PREDISPOSITION; ENTEROPATHY; GENE AMPLIFICATION; GENE FREQUENCY; GENOTYPE; GRANULOMA; IMMUNE DEFICIENCY; IMMUNOGENETICS; IMMUNOGLOBULIN DEFICIENCY; INFECTION RISK; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY;

COHORT STUDIES; COMMON VARIABLE IMMUNODEFICIENCY; CROHN DISEASE; EUROPE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREAT BRITAIN; HUMANS; MUTATION; NOD2 SIGNALING ADAPTOR PROTEIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 77955722388     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04216.x     Document Type: Article

References (43)

1. Chapel H, Cunningham-Rundles C. Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. Br J Haematol 2009 145 : 709 727.
2. Spickett GP. Current perspectives on common variable immunodeficiency (CVID). Clin Exp Allergy 2001 31 : 536 542.
3. Di Renzo M, Pasqui AL, Auteri A. Common variable immunodeficiency: a review. Clin Exp Med 2004 3 : 211 217.
4. Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999 93 : 190 197.
5. Chapel H, Lucas M, Lee M et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood 2008 112 : 277 286.
6. Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999 92 : 34 48.
7. Castigli E, Wilson SA, Garibyan L et al. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet 2005 37 : 829 834.
8. Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med 1997 127 : 613 617.
9. Bachwich PR, Lynch JP III., Larrick J, Spengler M, Kunkel SL. Tumor necrosis factor production by human sarcoid alveolar macrophages. Am J Pathol 1986 125 : 421 425.
10. Hunninghake GW. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Respir Dis 1984 129 : 569 572.
11. Müller-Quernheim J, Saltini C, Sondermeyer P, Crystal RG. Compartmentalized activation of the interleukin 2 gene by lung T lymphocytes in active pulmonary sarcoidosis. J Immunol 1986 137 : 3475 3483.
12. Takizawa H, Satoh M, Okazaki H et al. Increased IL-6 and IL-8 in bronchoalveolar lavage fluids (BALF) from patients with sarcoidosis: correlation with the clinical parameters. Clin Exp Immunol 1997 107 : 175 181.
13. Robinson BW, McLemore TL, Crystal RG. Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis. J Clin Invest 1985 75 : 1488 1495.
14. Hugot JP, Laurent-Puig P, Gower-Rousseau C et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996 379 : 821 823.
15. Ogura Y, Lala S, Xin W et al. Expression of NOD2 in Paneth cells: a pos
16. Opitz B, Püschel A, Schmeck B et al. Nucleotide-binding oligomerization domain proteins are innate immune receptors for internalized Streptococcus pneumoniae. J Biol Chem 2004 279 : 36426 (Pubitemid 17193303)
17. Sabbah A, Chang TH, Harnack R et al. Activation of innate immune antiviral responses by Nod2. Nat Immunol 2009 10 : 1073 1080.
18. Hugot JP, Chamaillard M, Zouali H et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 411 : 599 603.
19. Lesage S, Zouali H, Cézard JP et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002 70 : 845 857.
20. Ogura Y, Bonen DK, Inohara N et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001 411 : 603 606. (Pubitemid 37363443)
21. Ahmad T, Armuzzi A, Bunce M et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002 122 : 854 866.
22. Miceli-Richard C, Lesage S, Rybojad M et al. CARD15 mutations in Blau syndrome. Nat Genet 2001 29 : 19 20.
23. Kanazawa N, Okafuji I, Kambe N et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome. Blood 2005 105 : 1195 1197.
24. Rahman P, Bartlett S, Siannis F et al. CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. Am J Hum Genet 2003 73 : 677 681.
25. Holler E, Rogler G, Herfarth H et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplntation. Blood 2004 104 : 889 894.
26. Drewe E, Powell RJ. NOD2 and inflammatory disease. CPD Bull Immunol Allergy 2004 4 : 20 2.
27. Schreiber S. Inflammatory bowel disease: immunologic concepts. Hepatogastroenterology 2000 47 : 15 28.
28. Hugot JP, Zaccaria I, Cavanaugh J et al. Prevalence of CARD15/NOD2 mutations in caucasian healthy people. Am J Gastroenterol 2007 102 : 1259 1267.
29. Yamamoto S, Ma X. Role of Nod2 in the development of Crohn's disease. Microbes Infect 2009 11 : 912 918.
30. Rath HC, Schultz M, Freitag R et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001 69 : 2277 2285.
31. Tamboli CP, Neut C, Desreumaux P, Colombel JF. Dysbiosis in inflammatory bowel disease. Gut 2004 53 : 1 4.
32. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo controlled trials. Clin Infect Dis 2010 50 : 473 480.
33. Wehkamp J, Harder J, Weichenthal M et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004 53 : 1658 1664. (Pubitemid 30085386)
34. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW et al. Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote interleukin-17 production in human memory T cells. Immunity 2007 27 : 660 669.
35. Eckmann L, Karin M. NOD2 and Crohn's disease: loss or gain of function? Immunity 2005 22 : 661 667.
36. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004 5 : 800 808.
37. Yu JE, Knight AK, Radigan L et al. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J Allergy Clin Immunol 2009 124 : 349 356, 356 e1-3.
38. Kim YG, Park JH, Shaw MH, Franchi L, Inohara N, Núñez G. The cytosolic sensors Nod1 and Nod2 are critical for bacterial recognition and host defense after exposure to Toll-like receptor ligands. Immunity 2008 28 : 246 257.
39. Cho JH, Nicolae DL, Gold LH et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci USA 1998 95 : 7502 7507.
40. Satsangi J, Parkes M, Louis E et al. Two stage genome-wide search in inflammatory bowel disease provides evidence for susceptibility loci on chromosomes 3, 7 and 12. Nat Genet 1996 14 : 199 202.
41. Rioux JD, Silverberg MS, Daly MJ et al. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000 66 : 1863 1870.
42. Hampe J, Shaw SH, Saiz R et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999 65 : 1647 1655.
43. Duerr RH, Barmada MM, Zhang L, Pfützer R, Weeks DE. High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11-12. Am J Hum Genet 2000 66 : 1857 1862.